A decade ago, there were dire concerns that the biopharmaceutical industry was headed for a severe crisis. There was, it was thought, inadequate mammalian manufacturing capacity to support the development pipeline. In particular, fears grew about shortages of monoclonal antibodies, with their general low potency, need for repeated administration, and large amounts of protein — often many 100s kilograms, needed annually. The industry responded quickly, and multiple trends resulted from this crisi...